Ananda to attend Science in the City

Ananda Pharma PLC

01 September 2025

 

 1 September 2025

ANANDA PHARMA PLC

("Ananda" or the "Company")

Ananda to attend Science in the City

Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions and focused on endometriosis and chemotherapy induced peripheral neuropathy (CIPN), is pleased to announce that its senior leadership team will be attending the Science in the City International conference on September 11 and 12, 2025 in Bordeaux. Ananda will be represented by the Chairman, Charles Morgan, the Chief Executive Officer, Melissa Sturgess. Melissa is the guest speaker at the pre-conference Reception to be held on the 11^th September.  Megan Morris will be representing Ananda at the New York simulcast event.

Science in the City International, is a groundbreaking EU educational summit taking place in La Cité Du Vin, Bordeaux, France which is bringing together plant-based executives and healthcare leaders from around the world.

This event is an unique opportunity for international industry stakeholders, medical healthcare professionals, Functional and Integrative Medicine practitioners, and Community Healthcare Changemakers & Leaders to come together for a historical USA/France live event. Science in the City is focussed on Evidence-Based Emerging Topics that are shaping the future of plant-based healthcare.  Melissa will be speaking on the need for regulatory approved CBD therapeutics to provide easily accessible and cost-effective treatments for women suffering from endometriosis.  Endometriosis is a condition which affects 10% of women, for which there is no effective treatment.   

The team will be available for meetings with investors, potential partners, and media. Please contact Megan Morris on [e-mail] to schedule a meeting in Bordeaux or New York.

Melissa Sturgess, CEO, commented: "We are delighted to be attending this important event and I am personally delighted to be invited to give a Keynote speech on the need for regulatory approved CBD therapies in the treatment of endometriosis pain.  Women use unregulated CBD products and it is vital we provide them with regulatory approved therapeutics to treat this debilitating condition."

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

ANANDA PHARMA PLC	[phone]
	[e-mail]
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper	[phone] [e-mail]
SP ANGEL CORPORATE FINANCE LLP
Corporate Finance	[phone]
Richard Morrison
Josh Ray
Abigail Wayne	[e-mail]
Rob Rees	[e-mail]
YELLOW JERSEY PR Sarah MacLeod Charles Goodwin Zara McKinlay	[phone] [e-mail]

https://investors.anandapharma.co.uk/link/rJa1Me

 

END